Aktienanalyse zu Prokidney Corp (PROK)PROKProkidney Corp

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ProKidney Corp is currently trading at $1.83, with a 5-day price change of +13.66%, indicating a recent upward trend. However, the RSI is at 79.285, suggesting that the stock may be overbought in the short term. The company continues to report significant net losses, with a net income of -$28.42 million in Q2 2026, which raises concerns about its profitability. Additionally, insider selling has increased by 503.05% over the last month, indicating potential lack of confidence from insiders. Therefore, while there is some positive momentum, the risks associated with ongoing losses and insider activity suggest that it may be prudent to hold rather than buy at this time.